Last reviewed · How we verify
NCT05478551
Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
Phase 2, PHASE3 trial testing Botulinum Toxin in Scar in 12 participants. Participants enrolled and being followed up; not accepting new ones.
30 December 2026
Quick facts
| Lead sponsor | Henry Ford Health System |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 12 |
| Start date | 1 June 2022 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Botulinum Toxin — full drug profile →
- Normal saline
Conditions studied
- Scar — all drugs for Scar →
- Hypertrophic Scar — all drugs for Hypertrophic Scar →
Sponsor
Henry Ford Health System — full company profile →
Who can join
Adults 18 to 70, any sex, with Scar or Hypertrophic Scar. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy wounds compared to the control (normal saline) in a double-blinded randomized control trial. It will expand upon previous studies that have already demonstrated the safety and good tolerance profile of BTA. We will be conducting a split-scar study/study involving two biopsy sites in a singular patient, allowing them to serve as their own control. In keeping with the results from previously conducted studies, we hypothesize that the wounds treated with BTA will have significantly less evidence of scar formation than those sites treated with normal saline.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05478551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Botulinum Toxin
Trials testing the same drug.
- NCT03546959 — Dynamic Lycra Orthosis as an Adjunct to Botulinum Toxin-A Injection for Post-stroke Spasticity · NA · completed
- NCT02711995 — Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation · NA · completed
- NCT02623829 — Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study) · Phase 2 · completed
Other recruiting trials for Scar
Currently open trials in the same condition.
- NCT07130747 — Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section · NA · recruiting
- NCT06533072 — Infrared LED Lighting Application and Wound Healing · NA · recruiting
- NCT06386549 — Effect of a Tele-rehabilitation Programme in Children With Burns: a Randomized Controlled Trial · NA · recruiting
- NCT05408117 — Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color · NA · recruiting
- NCT05501327 — Dose Regimen Study of SLI-F06 in Healthy Volunteers · Phase 2 · recruiting
Other Henry Ford Health System trials
Trials by the same sponsor.
- NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
- NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
- NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
- NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
- NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05478551 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05478551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing